ATE502T1 - SALTS OF NON-TOXIC ACTIVATED ANION EXCHANGE RESINS WITH 2-(4'-(P-CHLOROBENZOYL)-PH ENOXY)-2-(METHYL)-PROPIONIC ACID, CAPABLE OF PERMANENT BINDING TO BILATE ACIDS, AND PHARMACEUTICALS CONTAINING THESE SALTS. - Google Patents

SALTS OF NON-TOXIC ACTIVATED ANION EXCHANGE RESINS WITH 2-(4'-(P-CHLOROBENZOYL)-PH ENOXY)-2-(METHYL)-PROPIONIC ACID, CAPABLE OF PERMANENT BINDING TO BILATE ACIDS, AND PHARMACEUTICALS CONTAINING THESE SALTS.

Info

Publication number
ATE502T1
ATE502T1 AT79104010T AT79104010T ATE502T1 AT E502 T1 ATE502 T1 AT E502T1 AT 79104010 T AT79104010 T AT 79104010T AT 79104010 T AT79104010 T AT 79104010T AT E502 T1 ATE502 T1 AT E502T1
Authority
AT
Austria
Prior art keywords
salts
group
chlorobenzoyl
resins
acids
Prior art date
Application number
AT79104010T
Other languages
German (de)
Inventor
Valerio Dr. Borzatta
Manlio Dr. Cristofori
Angelo Dr. Brazzi
Original Assignee
Alfa Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Farmaceutici S.P.A. filed Critical Alfa Farmaceutici S.P.A.
Application granted granted Critical
Publication of ATE502T1 publication Critical patent/ATE502T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
    • C08B15/05—Derivatives containing elements other than carbon, hydrogen, oxygen, halogens or sulfur
    • C08B15/06—Derivatives containing elements other than carbon, hydrogen, oxygen, halogens or sulfur containing nitrogen, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Phenolic Resins Or Amino Resins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A non-toxic anionic resin selected from resins having a polymeric reticulated skeleton of styrenic or acrylic type, inert to the digestive enzymes, having a molecular weight higher than 1000 and containing ionizable amino groups, resins having a cellulosic reticulated skeleton modified by the introduction of free or substituted amino groups and resins having a polysaccharide reticulated skeleton modified by the introduction of free or substituted amino groups. The resin is capable of binding itself permanently to the biliary acids and is salified with an acid corresponding to the general formula: <IMAGE> wherein: R' represents a hydrogen atom, an alkyl group having 1 to 3 carbon atoms, a hydroxyalkyl group having 1 to 3 carbon atoms, R represents a chlorine atom or a group selected from p-chlorobenzoyl, p-bromobenzoyl and p-fluorobenzoyl, W represents a group selected from OH, -N(R''')-CH(R'')-(CH2)n-COOH and O-CH2-COOH wherein n represents a number from 0 to 5, R'' represents a hydrogen atom, a benzyl, a phenyl or a phenyl substituted with an OH group, a lower alkyl, a lower alkoxyl or a lower hydroxyalkyl group and R''' represents a hydrogen atom or a lower alkyl.
AT79104010T 1978-12-21 1979-10-17 SALTS OF NON-TOXIC ACTIVATED ANION EXCHANGE RESINS WITH 2-(4'-(P-CHLOROBENZOYL)-PH ENOXY)-2-(METHYL)-PROPIONIC ACID, CAPABLE OF PERMANENT BINDING TO BILATE ACIDS, AND PHARMACEUTICALS CONTAINING THESE SALTS. ATE502T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT03631/78A IT1106718B (en) 1978-12-21 1978-12-21 PHARMACOLOGICALLY ACTIVE SALONIZED ANIONIC RESIN BASED COMPOSITIONS
EP79104010A EP0012804B2 (en) 1978-12-21 1979-10-17 Salts of a non toxic, activated anion exchange resin capable of establishing a stable binding with bile acids and 2-(4'-(p-chlorobenzoyl)-phenoxy)-2-(methyl)-propionic acid and pharmaceutical compositions comprising these salts

Publications (1)

Publication Number Publication Date
ATE502T1 true ATE502T1 (en) 1982-01-15

Family

ID=11110905

Family Applications (1)

Application Number Title Priority Date Filing Date
AT79104010T ATE502T1 (en) 1978-12-21 1979-10-17 SALTS OF NON-TOXIC ACTIVATED ANION EXCHANGE RESINS WITH 2-(4'-(P-CHLOROBENZOYL)-PH ENOXY)-2-(METHYL)-PROPIONIC ACID, CAPABLE OF PERMANENT BINDING TO BILATE ACIDS, AND PHARMACEUTICALS CONTAINING THESE SALTS.

Country Status (11)

Country Link
US (1) US4340585A (en)
EP (1) EP0012804B2 (en)
JP (1) JPS55115403A (en)
AT (1) ATE502T1 (en)
DE (1) DE2961714D1 (en)
DK (1) DK159660C (en)
ES (1) ES487019A1 (en)
GR (1) GR72734B (en)
IT (1) IT1106718B (en)
NO (1) NO794225L (en)
YU (1) YU313079A (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393145A (en) * 1979-05-01 1983-07-12 Etablissement Texcontor Anionic ion exchange resins with cholesterol-decreasing properties
CH655507B (en) * 1983-01-12 1986-04-30
US4818539A (en) * 1985-02-05 1989-04-04 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4790991A (en) * 1985-02-05 1988-12-13 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4747881A (en) * 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4843098A (en) * 1985-02-05 1989-06-27 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4851392A (en) * 1985-02-05 1989-07-25 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4877775A (en) * 1986-06-16 1989-10-31 E. I. Du Pont De Nemours And Company Polymeric aminosaccharides as antihypercholesterolemic agents
IT1190349B (en) * 1986-06-16 1988-02-16 Prodotti Formenti Srl PHARMACEUTICAL COMPOSITIONS WITH SEQUESTRANT ACTIVITY OF BILE ACIDS CONTAINING COLESTYRAMINE AS THE ACTIVE INGREDIENT, AND PROCEDURE TO PREPARE THEM
US5498678A (en) * 1992-12-21 1996-03-12 Rohm And Haas Company Suspension polymerization process for water-soluble monomers
US5451397A (en) * 1992-12-21 1995-09-19 Rohm And Haas Company Bile acid sequestrant
US6129910A (en) * 1993-06-02 2000-10-10 Geltex Pharmaceuticals, Inc. Water-insoluble noncrosslinked bile acid sequestrants
US5929184A (en) * 1993-06-02 1999-07-27 Geltex Pharmaceuticals, Inc. Hydrophilic nonamine-containing and amine-containing copolymers and their use as bile acid sequestrants
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5900475A (en) * 1994-06-10 1999-05-04 Geltex Pharmaceuticals, Inc. Hydrophobic sequestrant for cholesterol depletion
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5703188A (en) * 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5753262A (en) * 1995-06-07 1998-05-19 Aronex Pharmaceuticals, Inc. Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof
US6203785B1 (en) * 1996-12-30 2001-03-20 Geltex Pharmaceuticals, Inc. Poly(diallylamine)-based bile acid sequestrants
US6423754B1 (en) * 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
EP1572190B1 (en) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
MX366925B (en) 2010-11-04 2019-07-31 Albireo Ab Ibat inhibitors for the treatment of liver diseases.
US20130236541A1 (en) 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
JP6217938B2 (en) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー Bile acid recirculation inhibitors for the treatment of cholestatic liver disease in children
EA038594B1 (en) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
KR20160002773A (en) 2013-03-15 2016-01-08 루메나 파마수티컬즈, 인코포레이티드 Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
EP4424363B1 (en) 2019-02-12 2026-04-29 Mirum Pharmaceuticals, Inc. Methods for increasing growth in pediatric subjects having cholestatic liver disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB857194A (en) * 1957-07-05 1960-12-29 Clinical Products Ltd Therapeutic agents comprising ion-exchange resins
BE580490A (en) 1958-07-15 1960-01-08 Merck & Co Inc Compositions and methods for lowering the cholesterol content of the blood
FR4933M (en) * 1964-09-17 1967-03-28
NL7017227A (en) 1969-12-27 1971-06-29
GB1348642A (en) * 1970-10-15 1974-03-20 Howard A N Hypocholesterolaemic compositions
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol

Also Published As

Publication number Publication date
DK548279A (en) 1980-06-22
DK159660C (en) 1991-04-08
EP0012804A1 (en) 1980-07-09
EP0012804B2 (en) 1987-03-04
NO794225L (en) 1980-06-24
DK159660B (en) 1990-11-12
JPS55115403A (en) 1980-09-05
DE2961714D1 (en) 1982-02-18
ES487019A1 (en) 1980-10-01
JPS6327362B2 (en) 1988-06-02
EP0012804B1 (en) 1981-12-30
IT7803631A0 (en) 1978-12-21
GR72734B (en) 1983-12-01
YU313079A (en) 1983-02-28
US4340585A (en) 1982-07-20
IT1106718B (en) 1985-11-18

Similar Documents

Publication Publication Date Title
DE2961714D1 (en) Salts of non toxic, activated anion exchange resins capable of establishing a stable binding with bile acids and 2-(4&#39;-(p-chlorobenzoyl)-phenoxy)-2-(methyl)-propionic acid ans pharmaceutical compositions comprising these salts
ES2164152T3 (en) COMPOSITION CONTAINING A RETICULATED POLYMER TO REMOVE BILIARY SALTS FROM A PATIENT.
GB2255339A (en) Peptidyl derivatives
AU518470B2 (en) 2-(2-alkoxyethyl)-2:-hydroxy-6,7-benzomorphanes
DK0835888T3 (en) A non-crosslinked anion exchange resin and pharmaceutical composition containing it
LU91587I2 (en) Agomelatine and its pharmaceutically acceptable derivatives (VALDOXAN)
ES8604545A1 (en) Phenylacetic-acid derivatives, medicines containing these compounds and process for their preparation.
ATE25078T1 (en) 2-AMINO-3-ACYLAMINO-6-BENZYLAMINO-PYRIDINE DERIVATIVES WITH ANTI-EPILEPTIC ACTIVITY.
SE8205698D0 (en) N- (4- (3-AMINOPROPYL) AMINOBUTYL-2- (OMEGA-GUANIDINOFETIC ACID-AMIDO) -2-SUBSTITUTED ETHANAMIDE, SALTS THEREOF AND PROCEDURE FOR PREPARING THEREOF
ES482002A1 (en) PROCEDURE FOR THE PREPARATION OF NEW DERIVATIVES 5-FE- NILPIRAZOLICOS.
BR8202861A (en) COMPOUND COMPOSITION PHARMACEUTICAL PROCESS TO LOWER THE BLOOD PRESSURE OF HUMAN BEINGS PROCESS TO PREPARE A COMPOUND AND PROCESS TO PREPARE A PHARMACEUTICAL COMPOSITION
IE780952L (en) Phenylamino-phenylacetic acid amides
ES488387A1 (en) Condensed derivatives of pyrrolidine or piperidine, process for their preparation and composition containing them.
ES2070602T3 (en) PROCEDURE FOR THE MANUFACTURE OF FLOWERED ALPHA ACRYLATES.
ZA84571B (en) Compounds derived from amides of mercaptoacetic acid and from 3-mercaptopropionic acid and pharmaceutical compositions containing them
SE8200309L (en) GUANIDINOCYKLOHEXANKARBOXYLSYRADERIVAT
GB1447911A (en) Process for producing polyamines
DK513281A (en) PROCEDURES FOR THE PREPARATION OF 3-THIOVINYLCEPHALOSPRONES
AU532890B2 (en) N-substituted morpholine derivatives
GB1261004A (en) Ketones derived from -1-(2-hydroxyethyl)-piperazine
GB1477937A (en) Aminals of aromatic aldehydes
BG50993A1 (en) 2, 3, 5- three substituted oxazolydines and process for their preparation
GB2012268A (en) Substituted 1,4-cyclohexadienes
ATE60048T1 (en) AMINO COMPOUNDS AND FUNGICIDES CONTAINING THEM.
ES8307253A1 (en) Dioxazabicyclic derivatives

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee